Kornimate/medical-research-clean huggingface dataset:
long-term follow-up study of subjects with knee osteoarthritis who had administered furestem-oa kit inj. in k0701 study

Conditions: Knee Osteoarthritis

Summary: long-term follow-up study of subjects with knee osteoarthritis who had administered furestem-oa kit inj. in k0701 study


Eligibility criteria:
inclusion criteria: * those who participated in the k0701 clinical trial and received purestem-oa kit inj * those who understand and voluntarily sign an informed consent form exclusion criteria * none
implantation of the cochlear® nucleus® system in adults with single-sided deafness

Conditions: Single Sided Deafness

Summary: the objective of this feasibility study is to obtain preliminary safety and efficacy data associated with cochlear implantation in individuals with severe to profound sensorineural hearing loss contralateral to an ear with normal, or near-normal, hearing. the hypothesis is that restoration of hearing in the deafened ear will result in improved speech perception in the treated ear and advantages related to restoration of hearing to both ears.


Eligibility criteria:
inclusion criteria: 1. ability to provide informed consent. 2. eighteen years-of-age or older at the time of implantation. 3. presence of single-sided deafness as follows: 1. poorer ear (ear to be implanted): * severe to profound sensorineural hearing loss, defined as pure-tone thresholds 80 db hl or greater for the frequencies 500, 1000, 2000, 3000, and 4000 hz. * monosyllabic word understanding, as measured using the cnc word test at 60 dba under earphones, less than or equal to 10%. 2. better ear (contralateral ear): * normal or near-normal hearing, defined as pure-tone thresholds no poorer than 30 db hl at 250, 500, 1000, 2000, and 3000 hz and no poorer than 40 db hl at 4000 hz. * monosyllabic word understanding, as measured using the cnc word test at 60 dba under earphones, of greater than or equal to 90%. 4. duration of severe to profound sensorineural hearing loss of at least 6 months (to ensure stability of hearing loss) but no greater than 10 years. 5. english spoken as a primary language. exclusion criteria: 1. alleviation of tinnitus as the stated primary or sole motivation for seeking implantation by the subject and/or investigator. 2. actively using an implantable device in the poorer ear. 3. onset of severe to profound hearing loss \< 6 years-of-age. 4. evidence of active middle-ear pathology based on otologic examination and/or immittance testing. 5. medical or psychological conditions that contraindicate undergoing surgery. 6. ossification or any other cochlear anomaly at the implant ear that might prevent complete insertion of the electrode array. 7. hearing loss of neural or central origin, including auditory neuropathy. 8. unrealistic expectations on the part of the subject regarding the possible benefits, risks, and limitations inherent to the surgical procedure and prosthetic device. 9. unwillingness and/or inability of the candidate to comply with all investigational requirements including, but not limited to, study protocol and surgical procedure, as determined by the investigator.

Keywords: single sided deafness unilateral deafness unilateral hearing loss cochlear implantation
chidamide in combination with decitabine in non-hodgkin's lymphoma relapsed after chimeric antigen receptor

Conditions: Non Hodgkin Lymphoma

Summary: this is a phase i/ii clinical trial for patients with r/r non-hodgkin's lymphoma relapsed after chimeric antigen receptor t cells infusion. the purpose is to evaluate the safety and efficacy of the treatment with chidamide in combination with decitabine.


Eligibility criteria:
inclusion criteria: 1. subjects must have histological confirmation of non-hodgkin lymphoma (nhl) and relapsed after chimeric antigen receptor t cells infusion. 2. 18 to 65 years of age. 3. ecog performance of less than 2. 4. life expectancy of at least 3 months. 5. subjects with lymphoma must have at least one measureable new lesion \>1.5cm as defined by lymphoma response criteria. 6. subjects must have relapsed after chimeric antigen receptor t cells infusion without any intervention treatment prior to day 1. 7. subjects must have adequate marrow, live, renal and heart functions. exclusion criteria: 1. subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. 2. serious uncontrolled medical disorders or active infections, pulmonary infection especially. 3. active alimentary tract hemorrhage or history of alimentary tract hemorrhage in one month . 4. prior organ allograft. 5. women who are pregnant or breastfeeding. 6. women with a positive pregnancy test on enrollment or prior to investigational product administration. 7. subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
three-dimensional assessment of dentoskeletal changes associated with a modified twin block appliance

Conditions: Growth Modification

Summary: the aim of the current study is to evaluate the skeletal, dental, soft tissue, tmj, and upper airway size changes associated with a new design of twin block compared to the conventional twin block appliance. additionally, patients' satisfaction with the two designs will be assessed.

twin block appliance is the gold standard for the treatment of skeletal class ii patients with deficient mandible. yet, it has some drawbacks as proclination of the mandibular incisors, development of posterior open bite and the unesthetic appearance. many modifications in twin block a new design were made to overcome the previous problems, as adding incisor capping, clasps, sagittal blocks, and esthetic twin block appliances. in the current trial a new design of esthetic twin block appliance with sagittal blocks is investigated and the post treatment skeletal, dental, and soft tissue, tmj, and upper airway size will be assessed and compared to the changes associated with the conventional design of twin block. moreover, patient satisfaction with the appliance will be assessed with both appliances.

Eligibility criteria:
inclusion criteria: * skeletal class ii deficient mandible * class ii molar and canine relation * male growing patients cvm 2,3 age range 10-14 * normal vertical growth pattern * anb \> 4 * mild to moderate crowding exclusion criteria: * previous orthodontic treatment. * craniofacial syndrome. * periodontal disease. * extracted first permanent molars.

Keywords: twin block esthetic twin block clear twin block deficient mandible skeletal class ii
opioid free and therapy minimized advantages using hana table for total hip arthroplasty

Conditions: Arthropathy of Hip Joint; Osteoarthritis, Hip

Summary: to prove that anterior approach total hip arthroplasty using the hana table can be performed with little, if any, need for opioids using a combination of education, optimized pre op and post op pain protocols and optimized recovery tools.

methods: data collection: * pre-op assessment/physical therapy evaluation * post op assessment - pacu, phase ii (prior to discharge) * phone calls after discharge (post op day 1, 2, 3) * follow up assessment in surgeon's office (3 and 6 weeks post op) * ortech * swiftpath * hoos jr pre-optimization: * all patients enroll in swiftpath education program * optimized bmi, hemoglobin, albumin, glucose control, a1c and blood pressure control total joint procedure: -anterior approach using the hana table tha preformed with intra-articular block pain management regimen: * pre op pt teaching * post op multimodal pain regimen

Eligibility criteria:
inclusion criteria: * elective total hip arthroplasty * unilateral * patient surgeries scheduled to be performed at the hospital and surgery center * patients must enroll in swiftpath * ability to read and understand english exclusion criteria: * patient diagnosis of schizophrenia, bipolar disease, dementia * previous burn to affected extremity * bmi \> 40 * hemoglobin \<12 female, \<13 male * albumin less than 3.5 * a1c \>8.0
novel brominated and organophosphate flame retardants and type 2 diabetes

Conditions: Type 2 Diabetes; Novel Brominated Flame Retardants; Organophosphate Flame Retardants; Fasting Plasma Glucose

Summary: as alternative flame retardants (frs), novel brominated flame retardants (nbfrs) and organophosphate flame retardants (opfrs) are ubiquitous in environment and may cause endocrine disruption effects. the associations between traditional endocrine-disrupting chemicals (edcs) and type 2 diabetes have been extensively reported in epidemiological studies. to date, however, human-based evidence on the effects of nbfrs and opfrs is lacking. the investigators conducted a case-control study of 344 participants aged 25-80 years from shandong province, east china, to assess potential associations between serum nbfr and opfr concentrations and etiology of type 2 diabetes for the first time.

in this study, the investigators conducted a case-control study in shandong province, east china, to evaluate the associations between serum nbfr and opfr and risk of type 2 diabetes. the aims of the present study were to (1) evaluate the associations between alternative frs in human serum and the risk of type 2 diabetes, (2) assess the relationships between alternative fr concentrations and fasting plasma glucose (fpg), (3) investigate the correlations between alternative frs and concentrations of lipid fractions, including tg, tc, high-density lipoprotein cholesterol (hdl-c), and low-density lipoprotein cholesterol (ldl-c), and (4) clarify the joint effects of nbfr and opfr mixtures on the risk of type 2 diabetes

Eligibility criteria:
inclusion criteria: group of type 2 diabetes patients: 1. age 18 \~ 75 years old; 2. type 2 diabetes patients diagnosed in the first affiliated hospital of shandong first medical university (qianfoshan hospital of shandong province) , hba1c ≥7.0% and \<10.5% ; 3. patients signed informed consent. control group: 1. age 18 \~ 75 years old; 2. healthy population recruited from the first affiliated hospital of shandong first medical university (qianfoshan hospital of shandong province) ; 3. living in the monitoring area for more than 6 months within 12 months; 4. normal thyroid function and no history of thyroid cancer were needed in the control group; 5. fasting blood glucose level of 0.7 mmol/l was needed in the control group of type 2 diabetes mellitus without history of diabetes; 6. patients with informed consent. exclusion criteria: * group of type 2 diabetes: 1. pregnant, lactating women, patients with acute cardiac cerebrovascular disease; 2. patients with severe liver and renal impairment (related laboratory tests more than 2 times the normal) ; 3. patients with type 1 diabetes; 4. participants in other clinical trials within 3 months; 5. patients with malignant tumors. 6. has the disease and so on serious anemia, is not suitable to carry on the patient which the blood draws the test. control group: 1. patients with serious heart, liver or kidney disease; 2. patients with iodine or thyroid hormone; 3. patients with confirmed malignant tumor; 4. pregnant women or those who have recently taken contraception or estrogen.
lysine-specific demethylase 1 and salt-sensitivity in humans

Conditions: Healthy Subjects

Summary: the purpose of this study is to investigate the role dietary salt plays in epigenetic regulation of blood pressure, focusing on the salt-sensitive regulatory enzyme lysine-specific demethylase 1.

the purpose of this study is to investigate the role dietary salt plays in epigenetic regulation of blood pressure in african american and caucasians, focusing on the salt-sensitive regulatory enzyme lysine-specific demethylase 1. this might help us understand why some people develop high blood pressure. healthy volunteers will be screened for eligibility and invited to participate in a 2 weeks study. week 1 will be consumption of a low salt diet. week 2 will be a high salt diet. at the end of each week, participants will be admitted to a clinical research center overnight and for one day. on the crc, participants will remain fasting and supine overnight and then next morning undergo hormonal and vascular testing. this will consist of blood drawing, echocardiogram, vascular tonometry, and assessment of renal blood flow before and after a low-dose angiotensin ii infusion. the study outcome will compare how variants in the lsd1 gene affect hormonal and vascular responses according to race. this information will help us determine why some races and genetic profiles are more susceptible to detrimental effects of salt in the diet while others are protected against these effects.

Eligibility criteria:
inclusion criteria: * age 25-45 years * caucasian or african american * no gender preference (anticipate 50% female) * normotensive (screening blood pressure \<140/90 mmhg) * no history of hypertension, diabetes, stroke, coronary artery disease, kidney disease, cancer, thyroid disease, preeclampsia, or hospitalizations in 6 months * normal screening laboratory values (cmp, tsh, a1c) * normal ecg * bmi \<25 kg/m2 exclusion criteria: * pregnancy * breast feeding * any medication or herbal preparation * \>6oz alcohol/week * tobacco use * illicit drug use * chronic nsaid use * recent steroid use (injected, inhaled, oral) * decongestant use in the past 2 weeks * known sensitivity to infused angiotensin ii or para-amino hippurate
effectiveness of internet-based self-help act with behavioral activation in improving alcohol use abstinence among ethnic minority young adults with alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: the goal of this clinical trial is to examine the preliminary effectiveness and feasibility of internet-based self-help acceptance and commitment therapy with behavioral activation for ethnic minority young adults with alcohol use disorder. the main questions it aims to answer are: * is the internet-based self-help acceptance and commitment therapy with behavioral activation (self-help iact-ba) feasible and acceptable for ethnic minority young adults with aud? * does the self-help iact-ba promote greater abstinence from alcohol use compared to treatment as usual (tau) in ethnic minority young adults diagnosed with aud? researchers will compare self-help iact-ba to treatment as usual (tau) to see if self-help iact-ba works to treat alcohol use disorder in ethnic minority young adults. participants will: * received a self-help iact-ba module every week for 6 weeks. or a placebo every day for 4 months * access the module every week, read the material, practice, and complete home assignments.


Eligibility criteria:
inclusion criteria: * hong kong ethnic minority young adults * they have to read, write, and speak english * their age will range from 18 to 25 * they will be voluntary to participate * participants should have smartphones or other electronic devices to access the internet * they must have aud based on dsm-5 criteria. exclusion criteria: * currently having psychiatric problems, other mental health problems, being actively involved in suicidal attempts, or immediate care * having a plan to go out of hong kong during intervention implementation * having no access to the internet, smart telephone, or other electronic devices * have participated in another psychosocial or pharmacological intervention for aud.

Keywords: acceptance and commitment therapy behavioral activation ethnic minority young adults alcohol abuse alcohol use disorder
effects of sensomotoric training on neck/scapular pain in people with visual disability

Conditions: Neck/Scapular Pain

Summary: the purpose of this study is to determine whether sensomotoric training can reduce neck/scapular pain in people with visual disability.

people with prolonged musculoskeletal disorders have impaired quality of life, physical function, work conditions and work ability and consume substantial public resources. an often overlooked fact in this context is the relationship between musculoskeletal disorders and the importance of a normally functioning visual system. people who have a visual impairment in adulthood often experience reduced health and life satisfaction. many people lose their faith in order to continue with the activities previously carried out as to cope with their life, their work, and in some cases,personal care. rehabilitative efforts to reduce the negative effects often involve the prescription of various visual aids which, in turn, often leads to unfavourable ergonomic and static postures with further increased risk of musculoskeletal problems. a prevention of such disorders is likely to allow them to continue their work, which is important from both an individual and a society perspective. the overall objective of the project is to evaluate the effects of an intervention program and develop a theoretical model for the relationship between near work, eye disorders and musculoskeletal disorders. the intervention is to be evaluated in a randomized trial on people with impaired vision and pain in the neck and scapular area. an intervention based on development and adaptation of an established physiotherapy practice in order to increase body awareness, body control and movement patterns will be evaluated. the effects of the intervention will be measured by a variety of outcome measures derived from who's icf-model. an innovative solution for establishing proprioception and eye-hand coordination in everyday activities, the clinical kinematic assessment tool, will be used.

Eligibility criteria:
inclusion criteria: * visual disability * age 18 to 67 years old * pain in neck/scapular area * living in örebro county exclusion criteria: * deafness * musculoskeletal disease (such as multiple sclerosis, etc)

Keywords: musculoskeletal and neural physiological phenomena postural balance eye/hand coordination
a trial to evaluate the efficacy and safety of two concentrations of vbp-926 solution for the treatment of chemotherapy-associated paronychia in cancer patients

Conditions: Chemotherapy-Associated Paronychia

Summary: paronychia is inflammation of the skin surrounding the nail that leads to secondary infection. iatrogenic paronychia has been clearly associated with cancer chemotherapies. this phase-2 trial is a dose finding study and will evaluate topical vbp-926 solution against a vehicle control.


Eligibility criteria:
inclusion criteria: * males or females aged 18 years or older * acute paronychia developing during the course of their monotherapy or combination chemotherapy * involvement of at least one nail with a paronychia severity grading score of 1 or higher * eastern cooperative oncology group score ≤ 2 * life expectancy of at least 12 months as per the investigator's judgment * willing to provide written informed consent * individuals who are willing to not start any new products otc or prescription treatments for paronychia and discontinue any treatment the investigator feels may interfere with the evaluation of the test products * individuals who are already on antibiotics as prescribed by oncologist for any condition except paronychia * individuals who are willing to avoid using cosmetic products, creams, salves, or ointments to the treatment area(s) exclusion criteria: * mentally incompetent or unable or not willing to give written informed consent or meet study requirements * without a history of a cancer diagnosis * without history of cancer diagnosis using chemotherapy * patients with paronychia requiring surgical intervention at baseline * patients who are already on prescribed treatment for paronychia who are not willing to discontinue this treatment and only use study drug (no washout period required) * neutropenia (absolute neutrophil count \< 1500 cells/µl) * patient human immunodeficiency virus (hiv) infection * patients with any medical condition, including alcohol or drug abuse or mental incapacity / hypersensitive to the study drug, which in judgment of the investigator will interfere with the patient's participation in the study or evaluation of study results * have any medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk
first-pass recanalization with embotrap ii in acute ischemic stroke (free-ais)

Conditions: Acute Ischemic Stroke Due to Intracranial Large Artery Occlusion

Summary: this study is a prospective, open-label, multi-center, registry study, designed to to documents that embotrap ii usage as a thrombectomy device for emergency large vessel occlusion (elvo) in terms of the rate of first pass recanalization (fpr). patients with elvo will initially underwent mechanical thrombectomy usig embotrap ii. fpr is defined as modified tissue thrombolysis in cerebral ischemia (mtici) 2b or 3


Eligibility criteria:
inclusion criteria: 1. subjects experiencing acute ischemic stroke due to large vessel occlusion (intracranial internal carotid artery and middle cerebral artery m1 or proximal m2 segment, intracranial vertebral artery and basilar artery 2. age 19 or greater 3. mrs before qualifying stroke, 0 to 2 4. baseline nihss score 4 or more 5. ct aspects \> 5 or mr aspects \> 4 6. good collateral statues on ct angiogram (collateral grade by calgary group, 4 or 5) or corresponding to defuse 3 or dawn trial on perfusion imaging. 7. onset (last-seen-well) time to femoral puncture time \< 24 hours 8. anticipated life expectancy of at least 12 months 9. patients who undergo endovascular thrombectomy with embotrap ii as the first-line device 10. signed informed consent for study enrollment exclusion criteria: 1. multiple simultaneous large vessel occlusions 2. pregnancy 3. severe contrast allergy or absolute contraindication to iodinated contrast agent 4. patient has a severe or fatal combined illness that will prevent improvement of follow-up or will render the procedure unlikely to benefit the patient.